DPP-4 inhibitors × glycemic control

TrialAdvances in therapy2015

Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-naïve patients with type 2 diabetes: a double-blind randomized trial.

Linong Ji et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 689 people · 2015

Range includes no effect

No clear effect on glycemic control

−0.01percentage points−0.13 to +0.12

As reported

difference −0.01 %, 95% CI −0.13 to 0.12

+2 more in the walkthrough ↓

Three numbers in the abstract

the abstract, start to end

a mean baseline of 8.0% (64 mmol/mol) by -0.99% (-11 mmol/mol) for linagliptin + LD metformin, and -0.98% (-11 mmol/mol) for HD metformin [treatment difference -0.01% (95% confidence interval

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Change in glycated hemoglobin (HbA1c) from baseline to Week 14linagliptin + LD metformin vs baseline
−0.99
Change in glycated hemoglobin (HbA1c) from baseline to Week 14HD metformin vs baseline
−0.98
Glycemic control
−0.01−0.13 to 0.12
MetforminDPP-4 inhibitorsGlycemic controlAdverse events & safety
1 / 3

8 papers cite it

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 25805187